Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05329766 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
A Phase 2 study of Gastrointestinal Tract Malignancies, sponsored by Arcus Biosciences.
- Active
- Registry status
- Phase 2
- Development phase
- 332
- Enrollment target
- 20
- Study locations
NCT05329766 is a Phase 2 study of Gastrointestinal Tract Malignancies that is active but no longer recruiting, run by Arcus Biosciences. The registered enrollment target is 332 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT05329766, a Phase 2 study of Gastrointestinal Tract Malignancies, is active but no longer recruiting, sponsored by Arcus Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 332 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).
Conditions Studied
Interventions
- DRUG Fluorouracil
- DRUG Leucovorin
- DRUG Zimberelimab
- DRUG Quemliclustat
- DRUG Domvanalimab
Study Locations (20)
Other
- UHN - Princess Margaret Cancer Centre - Toronto
- Clínica San Carlos de Apoquindo - Las Condes
- Bradford Hill Centro de Investigaciones Clinicas - Recoleta
- Centro de Estudios Clínicos SAGA - Santiago
Florida
- Florida Cancer Specialist - South - Fort Myers
- Mayo Clinic - Jacksonville - Jacksonville
- Florida Cancer Specialist - North - St. Petersburg
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Ronald Reagan UCLA Medical Center - Santa Monica
New York
- Memorial Sloan Kettering Cancer Center - New York
- Columbia University - New York
Tennessee
- SCRI Tennessee Oncology - Nashville - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Arizona
- Mayo Clinic - Arizona - Phoenix
Connecticut
- Yale Cancer Center - Derby
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05329766
The ClinicalTrials.gov registry entry for NCT05329766 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastrointestinal Tract Malignancies appearing as the primary indexed condition, and to 5 interventions - of which Fluorouracil is the first listed.
NCT05329766 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT05329766 about?
NCT05329766 is a clinical study titled "A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies". The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin...
What is the current status of trial NCT05329766?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 332 participants. The study started on 2022-06-10. Estimated completion is 2027-06.
What conditions does trial NCT05329766 study?
This clinical trial studies the following conditions: Gastrointestinal Tract Malignancies.
What interventions are being tested in trial NCT05329766?
The interventions under investigation include: Fluorouracil (DRUG), Leucovorin (DRUG), Zimberelimab (DRUG), Quemliclustat (DRUG), Domvanalimab (DRUG).
Who is sponsoring clinical trial NCT05329766?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05329766 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.